Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases.

Maines LW, French KJ, Wolpert EB, Antonetti DA, Smith CD.

Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5022-31.

2.

VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability.

Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA.

Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5106-15.

PMID:
17065532
3.

Role for extracellular signal-responsive kinase-1 and -2 in retinal angiogenesis.

Bullard LE, Qi X, Penn JS.

Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1722-31.

PMID:
12657614
4.

Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor.

Yang W, Yu X, Zhang Q, Lu Q, Wang J, Cui W, Zheng Y, Wang X, Luo D.

Exp Eye Res. 2013 Oct;115:96-105. doi: 10.1016/j.exer.2013.06.011. Epub 2013 Jun 28.

PMID:
23810809
5.

VEGF-A165b is cytoprotective and antiangiogenic in the retina.

Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ.

Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4273-81. doi: 10.1167/iovs.09-4296. Epub 2010 Mar 17.

6.

Endothelial and glial cell interaction in diabetic retinopathy via the function of vascular endothelial growth factor (VEGF).

Sueishi K, Hata Y, Murata T, Nakagawa K, Ishibashi T, Inomata H.

Pol J Pharmacol. 1996 May-Jun;48(3):307-16. Review.

PMID:
9112668
7.

Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.

Deissler HL, Lang GK, Lang GE.

Exp Eye Res. 2014 May;122:20-31. doi: 10.1016/j.exer.2014.02.024. Epub 2014 Mar 11.

8.

Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy.

You JJ, Yang CH, Chen MS, Yang CM.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3447-55. doi: 10.1167/iovs.08-2603. Epub 2009 Mar 5.

PMID:
19264885
9.

Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture.

Castellon R, Caballero S, Hamdi HK, Atilano SR, Aoki AM, Tarnuzzer RW, Kenney MC, Grant MB, Ljubimov AV.

Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2758-66.

PMID:
12147613
10.

Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina.

Ved N, Hulse RP, Bestall SM, Donaldson LF, Bainbridge JW, Bates DO.

Clin Sci (Lond). 2017 Jun 1;131(12):1225-1243. doi: 10.1042/CS20170102. Epub 2017 Mar 24.

11.

Specific involvement of SRC family kinase activation in the pathogenesis of retinal neovascularization.

Werdich XQ, Penn JS.

Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5047-56.

PMID:
17065526
12.

Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo.

Yoo MH, Hyun HJ, Koh JY, Yoon YH.

Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7.

PMID:
16303979
13.

Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy.

Deng G, Moran EP, Cheng R, Matlock G, Zhou K, Moran D, Chen D, Yu Q, Ma JX.

Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5030-5042. doi: 10.1167/iovs.16-21402.

14.
16.

The cKit Inhibitor, Masitinib, Prevents Diabetes-Induced Retinal Vascular Leakage.

Kim SR, Im JE, Jeong JH, Kim JY, Kim JT, Woo SJ, Sung JH, Park SG, Suh W.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1201-6. doi: 10.1167/iovs.15-18065.

PMID:
26978025
17.

Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies.

Lupo G, Motta C, Giurdanella G, Anfuso CD, Alberghina M, Drago F, Salomone S, Bucolo C.

Biochem Pharmacol. 2013 Dec 1;86(11):1603-13. doi: 10.1016/j.bcp.2013.09.008. Epub 2013 Sep 25.

PMID:
24076420
18.

Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac).

Yoshida T, Gong J, Xu Z, Wei Y, Duh EJ.

Exp Eye Res. 2012 Jan;94(1):41-8. doi: 10.1016/j.exer.2011.11.003. Epub 2011 Nov 19.

19.

Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity.

McCollum GW, Rajaratnam VS, Bullard LE, Yang R, Penn JS.

Exp Eye Res. 2004 May;78(5):987-95.

PMID:
15051479
20.

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.

Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H.

N Engl J Med. 2005 Aug 25;353(8):782-92.

Supplemental Content

Support Center